IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma

Paulette Mhawech-Fauceglia, Francois R. Herrmann, Har Rai, Nana Tchabo, Shashikant Lele, Iyare Izevbaye, Kunle Odunsi, Richard T. Cheney

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Differentiating uterine serous carcinoma (USC) from endometrioid adenocarcinoma (EAC) could be problematic, especially in high-grade EACs and tumors exhibiting architectural variations. To address this issue, we evaluated 103 endometrial carcinoma cases using 4 immunomarkers, β-catenin, IMP3, PTEN, and p53. Cases included 31 USCs, 57 EACs, and 15 mixed EAC-USCs. Of 31 USCs and 57 EACs, 8 and 9, respectively, were considered diagnostically difficult and challenging. β-catenin was more frequently expressed in EAC (P = .001); p53, PTEN, and IMP3 were more frequently found in USC (P < .001 for each). IMP3 was the best independent predictive marker for USCs. The best marker combination for predicting USCs was PTEN+/IMP3+ (exact odds ratio, 163.87; 95% confidence interval, 19.62 to infinity; P < .001). IMP3 was consistently negative in all 9 challenging EAC cases and consistently positive in all 8 challenging USC cases. None of the markers or their combinations demonstrated any value in making the diagnosis of serous component in mixed EAC-USC tumors. IMP3 immunoexpression and the IMP3+/PTEN+ pattern are the best independent and combination markers, respectively, to predict USCs. We strongly recommend using them in difficult and challenging cases.

Original languageEnglish (US)
Pages (from-to)899-908
Number of pages10
JournalAmerican Journal of Clinical Pathology
Volume133
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Endometrioid Carcinoma
Endometrial Neoplasms
Carcinoma
Catenins
Neoplasms
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Mhawech-Fauceglia, P., Herrmann, F. R., Rai, H., Tchabo, N., Lele, S., Izevbaye, I., ... Cheney, R. T. (2010). IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. American Journal of Clinical Pathology, 133(6), 899-908. https://doi.org/10.1309/AJCPQDQXJ4FNRFQB
Mhawech-Fauceglia, Paulette ; Herrmann, Francois R. ; Rai, Har ; Tchabo, Nana ; Lele, Shashikant ; Izevbaye, Iyare ; Odunsi, Kunle ; Cheney, Richard T. / IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. In: American Journal of Clinical Pathology. 2010 ; Vol. 133, No. 6. pp. 899-908.
@article{191e47eb45d8469099368b5c21508bbc,
title = "IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma",
abstract = "Differentiating uterine serous carcinoma (USC) from endometrioid adenocarcinoma (EAC) could be problematic, especially in high-grade EACs and tumors exhibiting architectural variations. To address this issue, we evaluated 103 endometrial carcinoma cases using 4 immunomarkers, β-catenin, IMP3, PTEN, and p53. Cases included 31 USCs, 57 EACs, and 15 mixed EAC-USCs. Of 31 USCs and 57 EACs, 8 and 9, respectively, were considered diagnostically difficult and challenging. β-catenin was more frequently expressed in EAC (P = .001); p53, PTEN, and IMP3 were more frequently found in USC (P < .001 for each). IMP3 was the best independent predictive marker for USCs. The best marker combination for predicting USCs was PTEN+/IMP3+ (exact odds ratio, 163.87; 95{\%} confidence interval, 19.62 to infinity; P < .001). IMP3 was consistently negative in all 9 challenging EAC cases and consistently positive in all 8 challenging USC cases. None of the markers or their combinations demonstrated any value in making the diagnosis of serous component in mixed EAC-USC tumors. IMP3 immunoexpression and the IMP3+/PTEN+ pattern are the best independent and combination markers, respectively, to predict USCs. We strongly recommend using them in difficult and challenging cases.",
author = "Paulette Mhawech-Fauceglia and Herrmann, {Francois R.} and Har Rai and Nana Tchabo and Shashikant Lele and Iyare Izevbaye and Kunle Odunsi and Cheney, {Richard T.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1309/AJCPQDQXJ4FNRFQB",
language = "English (US)",
volume = "133",
pages = "899--908",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

Mhawech-Fauceglia, P, Herrmann, FR, Rai, H, Tchabo, N, Lele, S, Izevbaye, I, Odunsi, K & Cheney, RT 2010, 'IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma', American Journal of Clinical Pathology, vol. 133, no. 6, pp. 899-908. https://doi.org/10.1309/AJCPQDQXJ4FNRFQB

IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. / Mhawech-Fauceglia, Paulette; Herrmann, Francois R.; Rai, Har; Tchabo, Nana; Lele, Shashikant; Izevbaye, Iyare; Odunsi, Kunle; Cheney, Richard T.

In: American Journal of Clinical Pathology, Vol. 133, No. 6, 01.06.2010, p. 899-908.

Research output: Contribution to journalArticle

TY - JOUR

T1 - IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma

AU - Mhawech-Fauceglia, Paulette

AU - Herrmann, Francois R.

AU - Rai, Har

AU - Tchabo, Nana

AU - Lele, Shashikant

AU - Izevbaye, Iyare

AU - Odunsi, Kunle

AU - Cheney, Richard T.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Differentiating uterine serous carcinoma (USC) from endometrioid adenocarcinoma (EAC) could be problematic, especially in high-grade EACs and tumors exhibiting architectural variations. To address this issue, we evaluated 103 endometrial carcinoma cases using 4 immunomarkers, β-catenin, IMP3, PTEN, and p53. Cases included 31 USCs, 57 EACs, and 15 mixed EAC-USCs. Of 31 USCs and 57 EACs, 8 and 9, respectively, were considered diagnostically difficult and challenging. β-catenin was more frequently expressed in EAC (P = .001); p53, PTEN, and IMP3 were more frequently found in USC (P < .001 for each). IMP3 was the best independent predictive marker for USCs. The best marker combination for predicting USCs was PTEN+/IMP3+ (exact odds ratio, 163.87; 95% confidence interval, 19.62 to infinity; P < .001). IMP3 was consistently negative in all 9 challenging EAC cases and consistently positive in all 8 challenging USC cases. None of the markers or their combinations demonstrated any value in making the diagnosis of serous component in mixed EAC-USC tumors. IMP3 immunoexpression and the IMP3+/PTEN+ pattern are the best independent and combination markers, respectively, to predict USCs. We strongly recommend using them in difficult and challenging cases.

AB - Differentiating uterine serous carcinoma (USC) from endometrioid adenocarcinoma (EAC) could be problematic, especially in high-grade EACs and tumors exhibiting architectural variations. To address this issue, we evaluated 103 endometrial carcinoma cases using 4 immunomarkers, β-catenin, IMP3, PTEN, and p53. Cases included 31 USCs, 57 EACs, and 15 mixed EAC-USCs. Of 31 USCs and 57 EACs, 8 and 9, respectively, were considered diagnostically difficult and challenging. β-catenin was more frequently expressed in EAC (P = .001); p53, PTEN, and IMP3 were more frequently found in USC (P < .001 for each). IMP3 was the best independent predictive marker for USCs. The best marker combination for predicting USCs was PTEN+/IMP3+ (exact odds ratio, 163.87; 95% confidence interval, 19.62 to infinity; P < .001). IMP3 was consistently negative in all 9 challenging EAC cases and consistently positive in all 8 challenging USC cases. None of the markers or their combinations demonstrated any value in making the diagnosis of serous component in mixed EAC-USC tumors. IMP3 immunoexpression and the IMP3+/PTEN+ pattern are the best independent and combination markers, respectively, to predict USCs. We strongly recommend using them in difficult and challenging cases.

UR - http://www.scopus.com/inward/record.url?scp=77952959702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952959702&partnerID=8YFLogxK

U2 - 10.1309/AJCPQDQXJ4FNRFQB

DO - 10.1309/AJCPQDQXJ4FNRFQB

M3 - Article

VL - 133

SP - 899

EP - 908

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -